Cargando…
Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
Endocrine-resistance remains a major challenge in estrogen receptor α positive (ERα(+)) breast cancer (BC) treatment and constitutively active somatic mutations in ERα are a common mechanism. There is an urgent need to develop novel drugs with new mode of mechanism to fight endocrine-resistance. Giv...
Autores principales: | Wang, Yubo, Min, Jian, Deng, Xiangping, Feng, Tian, Hu, Hebing, Guo, Xinyi, Cheng, Yan, Xie, Baohua, Yang, Yu, Chen, Chun-Chi, Guo, Rey-Ting, Dong, Chune, Zhou, Hai-Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692362/ https://www.ncbi.nlm.nih.gov/pubmed/38045063 http://dx.doi.org/10.1016/j.apsb.2023.05.005 |
Ejemplares similares
-
Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011) -
Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
por: Xu, Zhichao, et al.
Publicado: (2022) -
SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer
por: Guo, Shanchun, et al.
Publicado: (2019) -
Development of Highly Efficient Estrogen Receptor β-Targeted Near-Infrared Fluorescence Probes Triggered by Endogenous Hydrogen Peroxide for Diagnostic Imaging of Prostate Cancer
por: He, Pei, et al.
Publicado: (2023) -
Advances in covalent drug discovery
por: Boike, Lydia, et al.
Publicado: (2022)